In recognition of multidisciplinary integrated cancer care, translational and clinical cancer research of excellence at the Vall d’Hebron University Hospital…
Josep Tabernero
The New England Journal of Medicine publishes today the results of the SUNLIGHT study, a Phase III clinical trial comparing…
Futibatinib, an advanced FGFR inhibitor, has demonstrated effectiveness in impeding tumor growth among patients with FGFR-altered tumors. What is Intrahepatic…
We are delighted to announce that our Director Josep Tabernero is among the selected candidates for the American Association for…
The annual ASCO Symposium on Gastrointestinal Cancers took place from 19-21 January. Josep Tabernero, Director of VHIO, presented the results…
Recently published in Nature Reviews Gastroenterology & Hepatology*, a comprehensive Review focused on gastric cancer and gastro-oesophageal junction cancer (GC-GOJC)…
Published today, Clarivate has revealed its annual #HighlyCited2022 researchers list. Featuring among the world’s elite scientists at academic research institutes and…
Co-authored by Ana Vivancos, Principal Investigator of VHIO’s Cancer Genomics Group, and VHIO’s Director Josep Tabernero, a News & Views…
The Coordination and Support Action “4.UNCAN.eu” had its official kick-off on September 8-9 2022 with a public event hosted by…
The multicenter randomized phase III BREAKWATER trial, spearheaded by VHIO, is the first to evaluate the combination of study drugs…
